Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention
about
Injecting drug use: A vector for the introduction of new hepatitis C virus genotypesCharacterization of Acute and Chronic Hepatitis B Virus Genotypes in CanadaIncreased Uptake of HCV Testing through a Community-Based Educational Intervention in Difficult-to-Reach People Who Inject Drugs: Results from the ANRS-AERLI StudyEmerging epidemic of hepatitis C virus infections among young nonurban persons who inject drugs in the United States, 2006-2012.Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.Preference, acceptability and implications of the rapid hepatitis C screening test among high-risk young people who inject drugs.Needle exchange programs for the prevention of hepatitis C virus infection in people who inject drugs: a systematic review with meta-analysis.Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for preventionEnding hepatitis C in the United States: the role of screening.Policy responses to viral hepatitis B and C among people who inject drugs in Member States of the WHO European region: a sub-analysis of the WHO 2013 global hepatitis policy survey.Evidence-based consensus on the diagnosis, prevention and management of hepatitis C virus disease.Hepatitis C surveillance among youth and young adults in New York City, 2009-2013.Methamphetamine injecting is associated with phylogenetic clustering of hepatitis C virus infection among street-involved youth in Vancouver, Canada.Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug usersAcceptability of Global Positioning System technology to survey injecting drug users' movements and social interactions: a pilot study from San Francisco, USA.A longitudinal study of hepatitis C virus testing and infection status notification on behaviour change in people who inject drugsAn international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential.HIV infection and hepatitis C virus genotype 1a are associated with phylogenetic clustering among people with recently acquired hepatitis C virus infection.Understanding differences in HIV/HCV prevalence according to differentiated risk behaviors in a sample of PWID in rural Puerto RicoLinkage to Care for Suburban Heroin Users with Hepatitis C Virus Infection, New Jersey, USA.Prevalence of HIV infection and risk behaviors among younger and older injecting drug users in the United States, 2009Increasing Infectious Endocarditis Admissions Among Young People Who Inject Drugs.Age and sharing of needle injection equipment in a cohort of Massachusetts injection drug users: an observational study.Novel interventions to prevent HIV and HCV among persons who inject drugs.Mixed HCV infection and reinfection in people who inject drugs--impact on therapy.Characteristics and Outcomes of Young Adult Opiate Users Receiving Residential Substance Abuse Treatment.Direct-acting antiviral agents for HCV infection affecting people who inject drugs.Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs.Initiating HCV treatment with direct acting agents in opioid agonist treatment: When to start for people co-infected with HIV?Update on pharmacotherapy for treatment of opioid use disorder.Risk Factor Analysis Between Newly Screened and Established Hepatitis C in GI and Hepatology Clinics.Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?Drug use and phylogenetic clustering of hepatitis C virus infection among people who use drugs in Vancouver, Canada: A latent class analysis approach.Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.Recommendations for the management of hepatitis C virus infection among people who inject drugs.Visits to primary care physicians among persons who inject drugs at high risk of hepatitis C virus infection: room for improvement.Strategies for hepatitis C testing and linkage to care for vulnerable populations: point-of-care and standard HCV testing in a mobile medical clinic.Rapid hepatitis C testing among persons at increased risk for infection--Wisconsin, 2012-2013.Iris abscess a rare presentation of intravenous drug abuse associated Candida endophthalmitis.Risk factors for HCV infection among young adults in rural New York who inject prescription opioid analgesics.
P2860
Q26781991-B030C42E-3E63-40DC-8305-25B1B02CB23BQ28548476-C2C9BC81-5551-43EC-B98E-F386FEA85B0BQ28550235-88AA4EC6-DF61-4BA4-8614-D5288924A617Q30209037-FAAC2C37-2517-4896-AB05-D3F36DD79F3AQ30429470-5AAD0977-B223-4435-A7FF-DC3D890075D0Q31168171-A03AED08-FE93-48F6-91B9-7EE8E03D6686Q33702754-AC102C5A-978B-467A-844B-2487C4E0A1A7Q33707925-B40EC840-0614-4DF3-ADBC-4019CAC94B42Q33862919-ED678536-0090-4029-A1A3-336296903A0FQ34260638-0B05FD80-2E39-4770-B0F5-14CAECE34B98Q35237341-78C24E66-AB3D-4724-B155-4382E7B5737DQ35543351-5DFFA42C-B3AC-4097-959A-4ADF48AD422EQ35703205-C8DC3436-0C7A-43D8-9291-0848A4432C19Q35864200-22ABE384-1E19-4FF1-8E3B-9AD09DA07923Q35878642-134B8ED7-F956-4B17-B2D0-770E3460A858Q35889562-441BD1C4-E444-420D-9322-6DFD71D155ECQ36090175-3BA4B382-ADC8-4872-9F24-543B504F1BB8Q36506119-4EA7860D-E156-4FED-9E1B-25BB5A036BD1Q36668343-C5463BA6-0570-4728-80F1-364E83AFEDF9Q36884996-91214172-0A57-46B9-A688-D272AB267BFBQ37040594-975DA8C4-C418-474A-ABF3-70A5A500924AQ37375396-7C8C9445-DC3D-4431-8591-2BD6E3F3A081Q37430582-E32E6528-659C-426D-B807-8AFB699CF7C1Q38318678-437ECA59-F05C-41CC-82D6-F2B7FCD30669Q38381584-97D74623-D3B9-4768-AF57-A1A81779235BQ38423484-FC0916F5-B30F-4885-AAD5-80EBAC38E40AQ38613271-898EB174-2CC3-41DA-BF5B-D5C11AA8266CQ38661825-27CFB714-7D20-41B9-97E2-12B1EE8051F0Q38746105-EF5D3250-75BF-40C4-BC25-EF7DDAC89E27Q38979423-26BB99C9-9863-42B0-A8EC-E5F1C335467AQ40039560-42DDE51B-2CF9-4B34-BF58-71EB93153279Q40092669-D8636320-B55C-493C-A84E-9C66F9BE1DA6Q40118634-AA1BC35F-BE80-4DD1-A5A6-C2372E54AE0FQ40565832-747E558B-71B6-4D6A-B472-2CD5274F2F38Q41047662-D16A847F-B27E-49C5-A29A-1014E6475290Q41546318-B92CD5DF-859F-4C59-85F3-AC5757EC20D6Q42199183-353FF04D-2945-40FF-A6F2-663FAF71AD42Q42225777-066F66E0-22F9-4414-A268-A366BD1D24DCQ50334319-8037ADEE-6A23-42D1-AB0F-D0E2ED780E91Q51816433-FEB300F2-D5F7-46C7-8920-88F497A61618
P2860
Injection drug use and hepatitis C virus infection in young adult injectors: using evidence to inform comprehensive prevention
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Injection drug use and hepatit ...... nform comprehensive prevention
@en
Injection drug use and hepatit ...... form comprehensive prevention.
@nl
type
label
Injection drug use and hepatit ...... nform comprehensive prevention
@en
Injection drug use and hepatit ...... form comprehensive prevention.
@nl
prefLabel
Injection drug use and hepatit ...... nform comprehensive prevention
@en
Injection drug use and hepatit ...... form comprehensive prevention.
@nl
P2860
P50
P356
P1476
Injection drug use and hepatit ...... nform comprehensive prevention
@en
P2093
Judith A Hahn
Meghan D Morris
P2860
P356
10.1093/CID/CIT300
P407
P478
57 Suppl 2
P577
2013-08-01T00:00:00Z